Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Nabriva Therapeutics
Nabriva Therapeutics
(NBRV)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Xenleta
Lefamulin
2019-08-19
2028-2031
Community-acquired infections
,
Bacterial pneumonia
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Lefamulin
healthy volunteers/patients
,
fibrosis
,
cystic fibrosis
,
infections
,
communicable diseases
,
bacterial infections
,
bacterial skin diseases
,
mycoplasma infections
,
pleuropneumonia
,
mycoplasma genitalium
,
pneumonia
Fosfomycin
infections
,
urinary tract infections
,
communicable diseases
,
pyelonephritis
Etrolizumab
infections
,
urinary tract infections
,
communicable diseases
,
pyelonephritis
Sodium chloride
healthy volunteers/patients
Bevifimod
pneumonia
Fcm
infections
,
urinary tract infections
,
communicable diseases
,
pyelonephritis
Periostat
mycoplasma infections
,
pleuropneumonia
,
mycoplasma genitalium
Trinessa
pneumonia
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use